Feedback regulated drug delivery systems MCQs With Answer

Feedback Regulated Drug Delivery Systems MCQs With Answer

Feedback-regulated (closed-loop) drug delivery systems are designed to sense a physiological signal and automatically adjust drug release in real time, improving safety and efficacy. For M. Pharm students, mastering their principles involves understanding biosensors, stimuli-responsive materials, control algorithms, and clinical performance metrics. This quiz focuses on key concepts such as glucose-responsive insulin delivery, enzyme- and ROS-responsive platforms, negative versus positive feedback, device time constants, biofouling, and safety interlocks. You’ll also encounter design trade-offs like set-point selection, hysteresis to prevent oscillations, and strategies to manage sensor drift. Use these MCQs to test and refine your understanding of how modern closed-loop systems translate biochemical cues into precise, adaptive therapeutics.

Q1. Which feature fundamentally defines a feedback-regulated (closed-loop) drug delivery system?

• Real-time sensing of a biomarker with on-board control that adjusts drug release
• Constant zero-order drug release independent of physiological conditions
• Patient-activated dosing via a manual push-button
• Preprogrammed time schedule without any sensing element

Correct Answer: Real-time sensing of a biomarker with on-board control that adjusts drug release

Q2. Which of the following is a typical endogenous signal used to drive feedback-regulated delivery?

• External magnetic field strength
• Blood glucose concentration
• Ultrasound amplitude
• Ambient light intensity

Correct Answer: Blood glucose concentration

Q3. What core component enables a closed-loop system to “sense” the need for drug release?

• Permeation enhancer
• Biosensor (chemical or biochemical sensor)
• Imaging contrast agent
• Cryoprotectant

Correct Answer: Biosensor (chemical or biochemical sensor)

Q4. Which statement best differentiates closed-loop from open-loop drug delivery?

• Closed-loop systems alter dosing based on real-time measurements, whereas open-loop systems do not measure or adapt
• Closed-loop systems are always implantable, open-loop are always oral
• Closed-loop systems have higher dose capacity than open-loop systems
• Closed-loop systems can only deliver peptides, not small molecules

Correct Answer: Closed-loop systems alter dosing based on real-time measurements, whereas open-loop systems do not measure or adapt

Q5. Phenylboronic acid (PBA)-functionalized polymers are widely studied in which feedback application?

• Glucose-responsive insulin delivery
• pH-independent gastric delivery
• Light-triggered retinal drug delivery
• Magnetically targeted chemotherapy

Correct Answer: Glucose-responsive insulin delivery

Q6. In glucose oxidase (GOx)-based insulin systems, how is insulin release typically triggered?

• GOx converts glucose to gluconic acid, lowering local pH and triggering hydrogel swelling or degradation that increases insulin release
• GOx heats the device via exothermic reaction and melts a polymer barrier
• GOx produces oxygen bubbles that push insulin out mechanically
• GOx directly binds insulin and transports it across membranes

Correct Answer: GOx converts glucose to gluconic acid, lowering local pH and triggering hydrogel swelling or degradation that increases insulin release

Q7. What is a major long-term challenge for implantable biosensors used in closed-loop delivery?

• Acute photobleaching
• Biofouling and fibrotic encapsulation reducing sensor sensitivity
• Instantaneous thermal runaway
• Radiofrequency incompatibility with all wearables

Correct Answer: Biofouling and fibrotic encapsulation reducing sensor sensitivity

Q8. To prevent rapid on–off oscillations around the set-point in closed-loop delivery, designers often introduce:

• High amplifier gain without limits
• A hysteresis window around the set-point
• Randomized dosing schedules
• Fixed-time bolus overrides

Correct Answer: A hysteresis window around the set-point

Q9. Which safety strategy helps prevent overdose if a sensor erroneously reads a persistently high biomarker level?

• Increasing controller gain to respond faster
• Disabling all alarms to avoid nuisance alerts
• A hard cap on maximum delivery rate and total dose
• Removing flow restrictors to reduce backpressure

Correct Answer: A hard cap on maximum delivery rate and total dose

Q10. For effective feedback regulation, which alignment is most critical?

• Device color matching to skin tone
• Response time (sensing-to-release) aligned with biomarker dynamics and drug pharmacokinetics
• Battery chemistry matched to drug solubility
• Reservoir geometry matched to packaging dimensions

Correct Answer: Response time (sensing-to-release) aligned with biomarker dynamics and drug pharmacokinetics

Q11. Which is a clinically adopted example of closed-loop drug delivery?

• Osmotic oral pump for nifedipine
• Transdermal fentanyl patch
• Hybrid closed-loop “artificial pancreas” (insulin pump + CGM + control algorithm)
• Copper intrauterine device

Correct Answer: Hybrid closed-loop “artificial pancreas” (insulin pump + CGM + control algorithm)

Q12. In negative feedback drug delivery, which statement is accurate?

• Drug release amplifies deviations of the biomarker from the set-point
• Drug release opposes deviations, driving the biomarker back toward the set-point
• Drug release is unrelated to biomarker changes
• Drug release is fixed by circadian rhythm only

Correct Answer: Drug release opposes deviations, driving the biomarker back toward the set-point

Q13. In closed-loop systems, the “set-point” refers to:

• The maximum rate at which the pump can deliver drug
• The target biomarker value the controller aims to maintain
• The volume of the drug reservoir
• The mass of polymer in the hydrogel matrix

Correct Answer: The target biomarker value the controller aims to maintain

Q14. A key limitation of phenylboronic acid-based glucose sensing at physiological pH is:

• Excessive thermal sensitivity near 37°C
• High pKa of PBA reduces glucose binding at pH 7.4 unless modified
• Inability to be copolymerized with hydrophilic monomers
• Spontaneous polymer depolymerization in plasma

Correct Answer: High pKa of PBA reduces glucose binding at pH 7.4 unless modified

Q15. Concanavalin A (Con A)-based glucose-responsive systems face which biocompatibility concern?

• Severe phototoxicity under ambient light
• Immunogenicity and potential lectin toxicity
• Extreme radio-opacity requiring shielding
• Pyrophoric reactions with oxygen

Correct Answer: Immunogenicity and potential lectin toxicity

Q16. Which approach best mitigates sensor drift in long-term closed-loop delivery?

• Relying solely on factory calibration
• Periodic in situ calibration with drift-correction algorithms
• Using a larger drug reservoir
• Adding a colorimetric indicator for user inspection

Correct Answer: Periodic in situ calibration with drift-correction algorithms

Q17. Enzyme-responsive systems for inflammation often leverage elevated levels of which enzymes to trigger drug release?

• Matrix metalloproteinases (MMPs)
• DNases
• Amylases
• Pepsin

Correct Answer: Matrix metalloproteinases (MMPs)

Q18. A common chemical design for hypoxia-responsive drug release relies on:

• Thermal melting of a wax barrier
• Photolysis of coumarin linkers
• Reduction of nitroimidazole groups under low oxygen to cleave linkers
• Hydrolysis by gastric acid

Correct Answer: Reduction of nitroimidazole groups under low oxygen to cleave linkers

Q19. In proportional control for closed-loop delivery, the release rate is commonly set to:

• A constant value regardless of measurements
• Increase proportionally with the difference between sensed biomarker and set-point
• Decrease randomly to avoid tolerance
• Mirror the circadian rhythm without sensing

Correct Answer: Increase proportionally with the difference between sensed biomarker and set-point

Q20. Which metric is most clinically meaningful to assess the performance of a closed-loop system?

• Total volume of the device
• Percentage of time the biomarker remains within the target range
• Number of Bluetooth connections per day
• Device mass loss during storage

Correct Answer: Percentage of time the biomarker remains within the target range

Download